{"name":"Anbogen Therapeutics, Inc.","slug":"anbogen-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"ABT-301","genericName":"ABT-301","slug":"abt-301","indication":"Other","status":"phase_1"},{"name":"ABT-101","genericName":"ABT-101","slug":"abt-101","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ABT-301","genericName":"ABT-301","slug":"abt-301","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABT-101","genericName":"ABT-101","slug":"abt-101","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQMDN4OW5IVXhoX000eXV4WVh3ZHJWVzVURW4tQjhLeFNGd2pyenU5MUdyaGV5aTFtSFREbXhCRXhqdHFWb21wcXlvcE5KajZHMkxRXzFMZDFjZS1TZzVHbmxqZVZCaGpOT1pRT3ZxUjVRUm9EUnptMU52NXRpWFFuSkdsR3I5QXRtQ3p6TlNaMW1NbEVRWDBwT3JodkZscHBOZHhHam1UV2VkTlJQZFBGRF9JVFlqR0otTDBYeQ?oc=5","date":"2025-08-04","type":"regulatory","source":"Applied Clinical Trials","summary":"FDA Clears Anbogen’s Oral HDAC1/2/3 Inhibitor for Phase I/II Colorectal Trial - Applied Clinical Trials","headline":"FDA Clears Anbogen’s Oral HDAC1/2/3 Inhibitor for Phase I/II Colorectal Trial","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}